Veracyte Stock News

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, M

While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.

Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.

Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Conference Call February 22, 2024 4:30 PM ET

Veracyte (VCYT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.05 per share a year ago.

The Zacks Medical - Instruments industry is gaining from the rising demand for digital health offers. However, inflation and staffing shortages continue to disrupt growth.

Here, we have picked five Cathie Wood stocks, Palantir (PLTR), Veracyte (VCYT), PagerDuty (PD), Roku (ROKU) and UiPath (PATH), which are well-poised for healthy returns in 2024.

Veracyte, Inc. (NASDAQ:VCYT ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Tristan Ribar – Vice President-Finance Marc Stapley – Chief Executive Officer Rebecc

Ahead of possible volatility in the market, investors may find some measure of confidence in undervalued stocks. From a psychological perspective, companies that sit well outside the well-beaten path

Veracyte's revenue sharply rose in the second quarter. The company is moving toward profitability.

Veracyte (VCYT) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.13 per share a year ago.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2023 after the close of market on Tuesday,

AI is coming to biotech in a big way. From protein folding to drug screening, from studying cells to studying populations, the AI boom has long been an asset to biological research and drug discovery.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate

Veracyte, Inc. (NASDAQ:VCYT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca